Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)

impe0096fc7.3 | Bone and Growth | IMPE2023

Serum phosphorus levels as a driver of skeletal morbidity in patients with fibrous dysplasia

Hasan Gun Zubeyir , Szymczuk Vivian , Taylor Jocelyn , III Osamor Charles , Boyce Alison

Objectives: Fibrous dysplasia (FD) is a rare disorder resulting in fractures, pain, and skeletal deformities. Abnormal osteoprogenitor cells produce excess FGF23, leading to hyperphosphaturia in most patients and frank hypophosphatemia in a smaller subset. Studies suggest that FGF23-mediated hypophosphatemia is associated with increased FD-related morbidity. However, the relationship between serum phosphorus levels and skeletal complications has not been inves...

impe0096p92 | Growth and Syndromes | IMPE2023

A Randomized Controlled Trial of Vosoritide in in Infants and Toddlers with Achondroplasia

E. Polgreen Lynda , Savarirayan Ravi , W. Wilcox William , Harmatz Paul , Phillips John , III , Tofts Louise , Ozono Keiichi , Arundel Paul , Irving Melita , A. Bacino Carlos , Basel Donald , B. Bober Michael , Charrow Joel , Mochizuki Hiroshi , Kotani Yumiko , M. Saal Howard , Jeha George , Han Lynn , Fisheleva Elena , Huntsman-Labed Alice , Day Jonathan

Background: Vosoritide increases annualized growth velocity (AGV) in children with achondroplasia aged 5 to 18 years. This global, phase 2, randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of vosoritide on growth in children with achondroplasia aged 3 months to <5 years.Methods: This study compared once-daily subcutaneous administration of vosoritide, at doses of 15 or 30 mg/kg of b...

impe0096p93 | Growth and Syndromes | IMPE2023

Medical complications in children with achondroplasia: learnings from PROPEL – a prospective clinical assessment study

Savarirayan Ravi , Maria De Bergua Josep , Arundel Paul , Pierre Salles Jean , Leiva-Gea Antonio , Saraff Vrinda , McDevitt Helen , Salcedo Maria , Nicolino Marc , Cormier-Daire Valerie , Kannu Peter , Skae Mars , B. Bober Michael , Phillips III John , Candler Toby , Harmatz Paul , Saal Howard , Hoover-Fong Julie , Weng Richard , Muslimova Elena , Cho Terry , Rogoff Daniela , Irving Melita

Background: Achondroplasia (ACH) is the most common short-limbed skeletal dysplasia, affecting between 1 in 15,000 to 1 in 30,000 live births. People with ACH are at risk for several significant co-morbidities, including foramen magnum stenosis, obstructive sleep apnea, chronic otitis media with conductive hearing loss, spinal stenosis, and a propensity towards obesity. PROPEL is a prospective, non-interventional study designed to examine baseline growth param...

impe0096p95 | Growth and Syndromes | IMPE2023

Bone mineral density in a cohort of children with ACH participating in the PROPEL studies

Savarirayan Ravi , Maria De Bergua Josep , Arundel Paul , Pierre Salles Jean , Leiva-Gea Antonio , Irving Melita , Saraff Vrinda , McDevitt Helen , Salcedo Maria , Nicolino Marc , Cormier-Daire Valerie , Kannu Peter , Skae Mars , B. Bober Michael , Phillips III John , Candler Toby , Harmatz Paul , Saal Howard , Hoover-Fong Julie , Muslimova Elena , Cho Terry , Weng Richard , Rogoff Daniela

Background: Achondroplasia (ACH) is the most common form of short-limbed skeletal dysplasias and is caused by an activating pathogenic variant of the fibroblast growth factor receptor 3 (FGFR3) gene. People with ACH are at risk for several significant co-morbidities, including foramen magnum stenosis, obstructive sleep apnea, chronic otitis media with conductive hearing loss, spinal stenosis, and a propensity towards obesity. Decreased bone mass was r...

impe0096p96 | Growth and Syndromes | IMPE2023

Bone age in children with achondroplasia: findings from a cohort of children participating in the PROPEL studies

Savarirayan Ravi , Maria De Bergua Josep , Arundel Paul , Pierre Salles Jean , Leiva-Gea Antonio , Irving Melita , Saraff Vrinda , McDevitt Helen , Salcedo Maria , Nicolino Marc , Cormier-Daire Valerie , Kannu Peter , Skae Mars , B. Bober Michael , Phillips III John , Candler Toby , Harmatz Paul , Saal Howard , Hoover-Fong Julie , Muslimova Elena , Cho Terry , Weng Richard , Rogoff Daniela

Background: Bone age (BA) is commonly used in pediatrics to define skeletal maturity for medical and non-medical purposes. Normal range is represented by 2 standard deviations (SDs) &pm; the mean. A BA > &pm;2 SDs from the chronological age (CA) is considered abnormal. BA in achondroplasia (ACH) has not been fully characterized; calculation is challenging given difficulties in comparing x-rays with standard radiographs if using the Greulich-Pyle (G&P) m...